Cardinal China Sell-Off Deal Advances
Executive Summary
The potential acquisition of Cardinal Health’s China business by Shanghai Pharmaceuticals could have significant strategic implications for the state-owned suitor, but it’s probably still “hard to assume” how the transaction may finally pan out. Expectations around the deal value are still in excess of $1bn, investor sources tell Scrip.
You may also be interested in...
Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration
The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
2017 Preview: Fresh Concerns And New Hopes In China
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.